Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drugs in donated blood.

R E Ferner1, J A Dunstan, S Chaplin

  • 1Wolfson Unit of Clinical Pharmacology, Royal Victoria Infirmary, Newcastle upon Tyne.

Lancet (London, England)
|July 8, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond clinical toxicology: protecting our poisoned patients.

Journal of the Royal Society of Medicine·2026
Same author

Analysis of substantiated welfare investigations in extensive farming systems in Victoria, Australia.

Australian veterinary journal·2024
Same author

Drug and therapeutics committees as guardians of safe and rational medicines use.

British journal of clinical pharmacology·2019
Same author

Crisis in the supply of medicines.

BMJ (Clinical research ed.)·2019
Same author

Secondary prevention after PCI: the cost-effectiveness of statin therapy in the Netherlands.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2015
Same author

Adverse drug reactions in dermatology.

Clinical and experimental dermatology·2015

Blood donation safety guidelines are proposed to protect recipients from drug treatments. The guidelines establish recommended waiting periods after the last drug dose for safe blood donation, preventing unnecessary donor deferrals.

Area of Science:

  • Pharmacology
  • Transfusion Medicine
  • Public Health

Background:

  • Donated blood from individuals with recent drug treatment poses potential risks to recipients.
  • Current guidelines for donor deferral may be overly restrictive, leading to unnecessary rejection of eligible donors.

Purpose of the Study:

  • To propose evidence-based guidelines for safe blood donation after drug treatment.
  • To minimize the risk of transmitting drug-related adverse effects to blood recipients.
  • To reduce the unnecessary deferral of blood donors.

Main Methods:

  • Review of pharmacokinetic and pharmacodynamic data for commonly used drugs.
  • Analysis of the time required for drug elimination and cessation of potential toxicity.
  • Development of a risk-benefit framework for drug-treated blood donors.

Related Experiment Videos

Main Results:

  • Specific recommended waiting periods between the last drug dose and blood donation for various drug classes.
  • Identification of drugs with minimal or no residual risk after a short deferral period.
  • Established criteria for safe blood donation balancing donor eligibility and recipient safety.

Conclusions:

  • Implementing these guidelines can enhance blood transfusion safety.
  • The proposed guidelines aim to optimize donor pool utilization while safeguarding recipients.
  • Evidence-based deferral periods are crucial for safe blood donation practices in the context of drug therapy.